Secondly, monotherapy with PI3K inhibitors inevitably has limited efficacy underscoring the importance of combination treatment with either chemotherapy or immunotherapy to yield their full therapeutic potential.15,16 These challenges associated with PI3K inhibition have led to an era of combination therapies to offer more effective tumor control. The gene discussed is PIK3CA; the disease is neoplasm.